Cogent Biosciences (COGT) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental analysis rates the stock neutral with a 5.2/10 quality. Strengths include a robust interest coverage (35×) and solid inventory turnover (103). Weaknesses are modest asset‑MV and revenue‑MV gaps and a 21% current‑liabilities ratio. Overall, fundamentals are moderate.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score3/3

Weight34.52%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.47%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.94%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value21.23

Score1/3

Weight-5.51%

1M Return-1.69%

PB-ROE

Value3.25

Score2/3

Weight32.20%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.28

Score2/3

Weight-1.22%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.00%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.19%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.78%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight51.06%

1M Return11.12%

Is COGT fundamentally strong?

COGT scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -73.70% ROE, 0.00% net margin, -17.26 P/E ratio, 8.92 P/B ratio, and -11.34% earnings growth, these metrics solidify its Netural investment rating.